Brokerages Set Bio-Rad Laboratories, Inc. (NYSE:BIO) PT at $498.50

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) have been assigned a consensus recommendation of “Buy” from the four analysts that are currently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued a report on the […]

Related Keywords

United States ,Canada ,America ,Michael Crowley ,Adara Wright ,Bio Rad Laboratories Inc ,Bio Rad Laboratories Company Profile ,Atlas Capital Advisors ,Financial Services ,Securities Exchange Commission ,Pacific Center ,Bio Rad Laboratories ,Get Free Report ,Exchange Commission ,Capital Advisors ,Finance Advisors ,Dark Forest Capital Management ,Forest Capital Management ,Rad Laboratories ,Get Free ,Life Science ,Clinical Diagnostics ,Bio Rad Laboratories Daily ,Nyse Bio ,Bio ,Medical ,09057220 ,Ratings ,Consensus ,